Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Genentech, Inc.
LG Chem
Maastricht University Medical Center
British Columbia Cancer Agency
University Medical Center Groningen
University of California, San Francisco